Total Payments
$261,662
2024 Payments
$57,936
Companies
27
Transactions
162
Medicare Patients
440
Medicare Billing
$85,910
Payment Breakdown by Category
Consulting$190,161 (72.7%)
Other$40,828 (15.6%)
Travel$24,344 (9.3%)
Research$4,190 (1.6%)
Food & Beverage$2,139 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $190,161 | 69 | 72.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,188 | 11 | 15.0% |
| Travel and Lodging | $24,344 | 22 | 9.3% |
| Unspecified | $4,190 | 9 | 1.6% |
| Food and Beverage | $2,139 | 50 | 0.8% |
| Honoraria | $1,640 | 1 | 0.6% |
Payments by Type
General
$257,472
153 transactions
Research
$4,190
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $60,542 | 58 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $33,023 | 13 | $0 (2024) |
| F. Hoffmann-La Roche AG | $31,055 | 12 | $0 (2024) |
| Incyte Corporation | $18,297 | 7 | $0 (2023) |
| Janssen Global Services, LLC | $17,503 | 6 | $0 (2023) |
| Merck Sharp & Dohme LLC | $15,250 | 3 | $0 (2023) |
| Genmab U.S., Inc. | $13,841 | 15 | $0 (2024) |
| Gilead Sciences, Inc. | $11,043 | 3 | $0 (2023) |
| Genentech USA, Inc. | $6,650 | 2 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $6,149 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $57,936 | 40 | F. Hoffmann-La Roche AG ($25,055) |
| 2023 | $101,220 | 74 | AbbVie Inc. ($38,584) |
| 2022 | $46,514 | 32 | E.R. Squibb & Sons, L.L.C. ($17,454) |
| 2021 | $55,991 | 16 | Incyte Corporation ($10,813) |
All Payment Transactions
162 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 12/10/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Consulting Fee | Cash or cash equivalent | $5,400.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | In-kind items and services | $59.54 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug), TECVAYLI | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 12/07/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 12/06/2024 | BeiGene USA, Inc. | — | Food and Beverage | In-kind items and services | $43.73 | General |
| 11/11/2024 | Genentech USA, Inc. | Lunsumio (Biological), Columvi, Polivy | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
| Category: BioOncology | ||||||
| 10/23/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,480.00 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Ipsen Bioscience Inc. | — | Consulting Fee | Cash or cash equivalent | $820.00 | General |
| 08/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,076.00 | General |
| 08/01/2024 | BTG International, Inc. | VORAXAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 07/26/2024 | PFIZER INC. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,160.00 | General |
| Category: Oncology | ||||||
| 07/26/2024 | BTG International, Inc. | VORAXAZE (Drug) | Food and Beverage | In-kind items and services | $67.63 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 07/18/2024 | Genmab A/S | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: Oncology | ||||||
| 07/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $135.00 | General |
| 07/15/2024 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $61.99 | General |
| 07/15/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $51.19 | General |
| 06/15/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 06/15/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $49.23 | General |
| 06/15/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $28.52 | General |
| 06/14/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $13,879.59 | General |
| 06/13/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $7,980.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | ABBVIE INC. | $1,650 | 2 |
| A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | AbbVie Inc. | $1,123 | 3 |
| PHASE II DIFFUSE LARGE B CELL LYMPHOMA DLBCL | NOVARTIS PHARMACEUTICALS CORPORATION | $776.00 | 1 |
| A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | ABBVIE INC. | $640.56 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 264 | 488 | $313,300 | $51,477 |
| 2022 | 5 | 165 | 268 | $190,150 | $32,537 |
| 2021 | 1 | 11 | 11 | $11,495 | $1,897 |
Total Patients
440
Total Services
767
Medicare Billing
$85,910
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 116 | 262 | $191,260 | $32,331 | 16.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 124 | $67,580 | $10,164 | 15.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 39 | $20,280 | $4,136 | 20.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $22,990 | $3,303 | 14.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 14 | $5,250 | $823.76 | 15.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 17 | 27 | $5,940 | $718.85 | 12.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 67 | 144 | $106,560 | $19,147 | 18.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 42 | 64 | $34,880 | $5,665 | 16.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $31,350 | $5,063 | 16.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $10,985 | $1,625 | 14.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 17 | $6,375 | $1,037 | 16.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $11,495 | $1,897 | 16.5% |
About Gilles Salles
Gilles Salles is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2021. The National Provider Identifier (NPI) number assigned to this provider is 1083389290.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Gilles Salles has received a total of $261,662 in payments from pharmaceutical and medical device companies, with $57,936 received in 2024. These payments were reported across 162 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($190,161).
As a Medicare-enrolled provider, Salles has provided services to 440 Medicare beneficiaries, totaling 767 services with total Medicare billing of $85,910. Data is available for 3 years (2021–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 08/10/2021
- Last Updated 08/10/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1083389290
Products in Payments
- IMBRUVICA (Drug) $14,058
- VENCLEXTA (Drug) $9,014
- Epkinly (Drug) $8,791
- Lunsumio (Biological) $6,650
- EPKINLY (Drug) $5,610
- CARVYKTI (Drug) $5,472
- Tazverik (Drug) $3,480
- Aliqopa (Drug) $3,175
- Yescarta (Drug) $3,020
- BRUKINSA (Drug) $2,266
- ADCETRIS (Biological) $2,160
- KYMRIAH (Biological) $2,086
- ORILISSA (Drug) $1,650
- TAZVERIK (Drug) $1,640
- VORAXAZE (Drug) $1,068
- Columvi (Biological) $16.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205